ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 04 Jan 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Sorafenib 200 mg tablet; and
  • Lenvatinib 4 mg and 10 mg capsules
for treating locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

Subsidy status

Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.

Lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.


Lenvatinib and sorafenib for treating differentiated thyroid cancer (4 Jan 2022) PES Lenvatinib and sorafenib for treating differentiated thyroid cancer (Published 4 Jan 2022)